Cargando…
Cnp Promoter-Driven Sustained ERK1/2 Activation Increases B-Cell Activation and Suppresses Experimental Autoimmune Encephalomyelitis
The ERK1/2 signaling pathway promotes myelin wrapping during development and remyelination, and sustained ERK1/2 activation in the oligodendrocyte (OL) lineage results in hypermyelination of the CNS. We therefore hypothesized that increased ERK1/2 signaling in the OL lineage would 1) protect against...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7691909/ https://www.ncbi.nlm.nih.gov/pubmed/33228381 http://dx.doi.org/10.1177/1759091420971916 |
_version_ | 1783614394898317312 |
---|---|
author | Jeffries, Marisa A. Obr, Alison E. Urbanek, Kelly Fyffe-Maricich, Sharyl L. Wood, Teresa L. |
author_facet | Jeffries, Marisa A. Obr, Alison E. Urbanek, Kelly Fyffe-Maricich, Sharyl L. Wood, Teresa L. |
author_sort | Jeffries, Marisa A. |
collection | PubMed |
description | The ERK1/2 signaling pathway promotes myelin wrapping during development and remyelination, and sustained ERK1/2 activation in the oligodendrocyte (OL) lineage results in hypermyelination of the CNS. We therefore hypothesized that increased ERK1/2 signaling in the OL lineage would 1) protect against immune-mediated demyelination due to increased baseline myelin thickness and/or 2) promote enhanced remyelination and thus functional recovery after experimental autoimmune encephalomyelitis (EAE) induction. Cnp-Cre;Mek1DD-eGFP/+ mice that express a constitutively active form of MEK1 (the upstream activator of ERK1/2) in the OL lineage, exhibited a significant decrease in EAE clinical severity compared to controls. However, experiments using tamoxifen-inducible Plp-Cre(ERT);Mek1DD-eGFP/+ or Pdgfrα-Cre(ERT);Mek1DD-eGFP mice revealed this was not solely due to a protective or reparative effect resulting from MEK1DD expression specifically in the OL lineage. Because EAE is an immune-mediated disease, we examined Cnp-Cre;Mek1DD-eGFP/+ splenic immune cells for recombination. Surprisingly, GFP(+) recombined CD19(+) B-cells, CD11b(+) monocytes, and CD3(+) T-cells were noted when Cre expression was driven by the Cnp promoter. While ERK1/2 signaling in monocytes and T-cells is associated with proinflammatory activation, fewer studies have examined ERK1/2 signaling in B-cell populations. After in vitro stimulation, MEK1DD-expressing B-cells exhibited a 3-fold increase in CD138(+) plasmablasts and a 5-fold increase in CD5(+)CD1d(hi) B-cells compared to controls. Stimulated MEK1DD-expressing B-cells also exhibited an upregulation of IL-10, known to suppress the initiation of EAE when produced by CD5(+)CD1d(hi) regulatory B-cells. Taken together, our data support the conclusion that sustained ERK1/2 activation in B-cells suppresses immune-mediated demyelination via increasing activation of regulatory B10 cells. |
format | Online Article Text |
id | pubmed-7691909 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-76919092020-12-04 Cnp Promoter-Driven Sustained ERK1/2 Activation Increases B-Cell Activation and Suppresses Experimental Autoimmune Encephalomyelitis Jeffries, Marisa A. Obr, Alison E. Urbanek, Kelly Fyffe-Maricich, Sharyl L. Wood, Teresa L. ASN Neuro Original Article The ERK1/2 signaling pathway promotes myelin wrapping during development and remyelination, and sustained ERK1/2 activation in the oligodendrocyte (OL) lineage results in hypermyelination of the CNS. We therefore hypothesized that increased ERK1/2 signaling in the OL lineage would 1) protect against immune-mediated demyelination due to increased baseline myelin thickness and/or 2) promote enhanced remyelination and thus functional recovery after experimental autoimmune encephalomyelitis (EAE) induction. Cnp-Cre;Mek1DD-eGFP/+ mice that express a constitutively active form of MEK1 (the upstream activator of ERK1/2) in the OL lineage, exhibited a significant decrease in EAE clinical severity compared to controls. However, experiments using tamoxifen-inducible Plp-Cre(ERT);Mek1DD-eGFP/+ or Pdgfrα-Cre(ERT);Mek1DD-eGFP mice revealed this was not solely due to a protective or reparative effect resulting from MEK1DD expression specifically in the OL lineage. Because EAE is an immune-mediated disease, we examined Cnp-Cre;Mek1DD-eGFP/+ splenic immune cells for recombination. Surprisingly, GFP(+) recombined CD19(+) B-cells, CD11b(+) monocytes, and CD3(+) T-cells were noted when Cre expression was driven by the Cnp promoter. While ERK1/2 signaling in monocytes and T-cells is associated with proinflammatory activation, fewer studies have examined ERK1/2 signaling in B-cell populations. After in vitro stimulation, MEK1DD-expressing B-cells exhibited a 3-fold increase in CD138(+) plasmablasts and a 5-fold increase in CD5(+)CD1d(hi) B-cells compared to controls. Stimulated MEK1DD-expressing B-cells also exhibited an upregulation of IL-10, known to suppress the initiation of EAE when produced by CD5(+)CD1d(hi) regulatory B-cells. Taken together, our data support the conclusion that sustained ERK1/2 activation in B-cells suppresses immune-mediated demyelination via increasing activation of regulatory B10 cells. SAGE Publications 2020-11-23 /pmc/articles/PMC7691909/ /pubmed/33228381 http://dx.doi.org/10.1177/1759091420971916 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by-nc/4.0/ Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Original Article Jeffries, Marisa A. Obr, Alison E. Urbanek, Kelly Fyffe-Maricich, Sharyl L. Wood, Teresa L. Cnp Promoter-Driven Sustained ERK1/2 Activation Increases B-Cell Activation and Suppresses Experimental Autoimmune Encephalomyelitis |
title | Cnp Promoter-Driven Sustained ERK1/2
Activation Increases B-Cell Activation and Suppresses Experimental
Autoimmune Encephalomyelitis |
title_full | Cnp Promoter-Driven Sustained ERK1/2
Activation Increases B-Cell Activation and Suppresses Experimental
Autoimmune Encephalomyelitis |
title_fullStr | Cnp Promoter-Driven Sustained ERK1/2
Activation Increases B-Cell Activation and Suppresses Experimental
Autoimmune Encephalomyelitis |
title_full_unstemmed | Cnp Promoter-Driven Sustained ERK1/2
Activation Increases B-Cell Activation and Suppresses Experimental
Autoimmune Encephalomyelitis |
title_short | Cnp Promoter-Driven Sustained ERK1/2
Activation Increases B-Cell Activation and Suppresses Experimental
Autoimmune Encephalomyelitis |
title_sort | cnp promoter-driven sustained erk1/2
activation increases b-cell activation and suppresses experimental
autoimmune encephalomyelitis |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7691909/ https://www.ncbi.nlm.nih.gov/pubmed/33228381 http://dx.doi.org/10.1177/1759091420971916 |
work_keys_str_mv | AT jeffriesmarisaa cnppromoterdrivensustainederk12activationincreasesbcellactivationandsuppressesexperimentalautoimmuneencephalomyelitis AT obralisone cnppromoterdrivensustainederk12activationincreasesbcellactivationandsuppressesexperimentalautoimmuneencephalomyelitis AT urbanekkelly cnppromoterdrivensustainederk12activationincreasesbcellactivationandsuppressesexperimentalautoimmuneencephalomyelitis AT fyffemaricichsharyll cnppromoterdrivensustainederk12activationincreasesbcellactivationandsuppressesexperimentalautoimmuneencephalomyelitis AT woodteresal cnppromoterdrivensustainederk12activationincreasesbcellactivationandsuppressesexperimentalautoimmuneencephalomyelitis |